SVR12 rates, incidence of adverse events (AEs) and treatment discontinuation due to AE were determined. Results: 209 prior null responders were included; 122 (58.4%) were male, 186 (89.0%) were white, 110 (52.6%) were <55 years of age. Selleckchem PR171 SVR12 was achieved in 200/209 patients (95.7%, table), and similar SVR12 rates were observed in GT1a and GT1b null responders. All 32 GT1b-infected patients who received

3D without RBV achieved SVR12 (100%). AEs occurring in >10% of patients were headache, fatigue, nausea, asthenia, insomnia, diarrhea and pruritus. Most AEs were mild, and the rates of SAEs and study drug discontinuations due to AEs were low (3.3% and 1.0% overall, respectively). Conclusions: In beta-catenin activation two phase 3 trials, treatment with a potent combination of direct acting antivirals (3D) with or without RBV resulted in high SVR12 rates in patients who were prior pegIFN/RBV null responders, historically

a difficult to treat population. Rates were similar regardless of 1a or 1b subgenotype, and there were few SAEs or study drug discontinuations due to AEs. Disclosures: Ira M. Jacobson – Consulting: Abbvie, Achillion, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Idenix, Genentech, Merck, Janssen, Vertex; Grant/ Research Support: Abbvie, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Novartis, Genentech, Merck, Janssen, Vertex; Speaking and Teaching: Bristol Myers Squibb, Gilead, Genentech, Vertex, Janssen Jean-Francois J. DuFour – Advisory Committees or Review Panels: Bayer, Gil-ead, Janssen, BMS, Jennerex, Merck, Novartis, Roche; Speaking and Teaching: Bayer, Boehringer-Ingelheim, Novartis, Roche Jeffrey Enejosa – Employment: AbbVie; Stock 上海皓元 Shareholder: AbbVie Robert J. de Knegt – Advisory

Committees or Review Panels: MSD, Roche, Norgine, Janssen Cilag; Grant/Research Support: Gilead, MSD, Roche, Janssen Cilag, BMS; Speaking and Teaching: Gilead, MSD, Roche, Janssen Cilag Peter Ferenci – Advisory Committees or Review Panels: Roche, Idenix, MSD, Jans-sen, AbbVie, BMS, Tibotec, BVdhringer Ingelheim; Patent Held/Filed: Madaus Rottapharm; Speaking and Teaching: Roche, Gilead, Roche, Gilead, Salix Hendrik Reynaert – Advisory Committees or Review Panels: MSD, Gillead, Jans-sen, BMS, Abbvie; Grant/Research Support: Roche Adrian M. Di Bisceglie – Grant/Research Support: Genentech, Gilead, AbbVie, BMS Lois Larsen – Employment: AbbVie; Stock Shareholder: AbbVie Tolga Baykal – Employment: AbbVie Lino Rodrigues-Jr – Employment: Abbvie Thomas Podsadecki – Employment: AbbVie; Stock Shareholder: AbbVie Donald M.